Who are Glipizide and Glargine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glipizide-and-glargine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Glipizide and Glargine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glipizide and Glargine (Glipizide and Glargine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin secretagogue + Long-acting insulin. Area: Diabetes.

marketed Insulin secretagogue + Long-acting insulin ATP-sensitive potassium channel (glipizide); Insulin receptor (glargine) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Glipizide and Glargine (Glipizide and Glargine) — Cook County Health. Glipizide stimulates insulin secretion from pancreatic beta cells, while glargine provides long-acting basal insulin replacement to lower blood glucose.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Glipizide and Glargine TARGET	Glipizide and Glargine	Cook County Health	marketed	Insulin secretagogue + Long-acting insulin	ATP-sensitive potassium channel (glipizide); Insulin receptor (glargine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin secretagogue + Long-acting insulin class)

Cook County Health · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glipizide and Glargine — Competitive Intelligence Brief. https://druglandscape.com/ci/glipizide-and-glargine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab